Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.
Christof Vulsteke, MD, PhD
Advertisement
Christof Vulsteke, MD, PhD, is head of Integrated Cancer Center Ghent (IKG, Belgium) and Clinical Trial Unit Oncology Ghent.
Articles by Christof Vulsteke, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
2
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
3
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
4
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
5